3,5,4'-trihydroxy-trans-stilbene

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

acne

[Insufficient Evidence]

Dose: apply 1 mcg/g gel topically qhs

allergic rhinitis, adult pts

[Possibly Effective]

Dose: 2 sprays in each nostril tid; Info: 0.1% spray

allergic rhinitis, peds pts

[Possibly Effective]

Dose: 2 sprays in each nostril tid; Info: 0.05% spray; for pts 4-17 yo

cognitive decline, age-related

[Insufficient Evidence]

Dose: 75 mg PO bid; Alt: 200-1000 mg PO qd

COPD

[Insufficient Evidence]

Dose: 10 mg PO qd x20 days/mo, then repeat tx course qmo

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 250-1000 mg PO qd

diabetic nephropathy

[Insufficient Evidence]

Dose: 500 mg PO qd; Info: used w/ losartan

obesity

[Possibly Effective]

Dose: 8-3000 mg PO qd

osteoarthritis

[Insufficient Evidence]

Dose: 500 mg PO qd; Info: used w/ meloxicam

osteopenia

[Insufficient Evidence]

Dose: 25 mg PO qd

periodontitis

[Insufficient Evidence]

Dose: 480 mg PO qd; Info: used w/ non-surgical tx

peritoneal dialysis

[Insufficient Evidence]

Dose: 150-450 mg PO qd

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 800-1500 mg PO qd

rheumatoid arthritis

[Insufficient Evidence]

Dose: 1 g PO qd; Info: used w/ antirheumatic tx

sciatica

[Insufficient Evidence]

Dose: 50 mg PO qd; Info: used w/ alpha-lipoic acid, acetyl-L-carnitine and cholecalciferol

ulcerative colitis

[Insufficient Evidence]

Dose: 500 mg PO qd